NASDAQ: TGTX
Tg Therapeutics Inc Stock

$36.01-1.36 (-3.64%)
Updated Jun 13, 2025
TGTX Price
$36.01
Fair Value Price
N/A
Market Cap
$5.72B
52 Week Low
$16.21
52 Week High
$46.48
P/E
133.37x
P/B
24.09x
P/S
14.97x
PEG
1.23x
Dividend Yield
N/A
Revenue
$386.39M
Earnings
$39.15M
Gross Margin
87.4%
Operating Margin
18.21%
Profit Margin
10.1%
Debt to Equity
1.77
Operating Cash Flow
-$61M
Beta
1.91
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

TGTX Overview

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine TGTX's potential to beat the market

CHold
  • Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More

Zen Rating Component Grades

C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
TGTX
Ranked
#49 of 464

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important TGTX news, forecast changes, insider trades & much more!

TGTX News

Overview

Due Diligence Score

Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TGTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

TGTX ($36.01) is trading above its intrinsic value of $11.74, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
TGTX is poor value based on its earnings relative to its share price (133.37x), compared to the US market average (31.36x)
P/E vs Market Valuation
TGTX is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more TGTX due diligence checks available for Premium users.

Valuation

TGTX price to earnings (PE)

For valuing profitable companies with steady earnings

Company
133.37x
Industry
-108.97x
Market
31.36x
TGTX is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
TGTX is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation

TGTX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
24.09x
Industry
4.66x
TGTX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

TGTX price to earnings growth (PEG)

For valuing profitable companies with growth potential

TGTX is poor value relative... subscribe to Premium to read more.
PEG Value Valuation

TGTX's financial health

Profit margin

Revenue
$120.9M
Net Income
$5.1M
Profit Margin
4.2%
TGTX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
TGTX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$656.7M
Liabilities
$419.4M
Debt to equity
1.77
TGTX's short-term assets ($644.51M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TGTX's short-term assets ($644.51M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TGTX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
TGTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$28.7M
Investing
-$12.9M
Financing
-$6.1M
TGTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

TGTX vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
TGTXC$5.72B-3.64%133.37x24.09x
IONSC$5.66B-0.08%-11.90x11.91x
NUVLF$5.62B+0.42%-17.78x5.56x
TLXC$5.39B-7.85%N/A15.07x
AXSMC$5.13B-2.02%-18.04x96.34x

Tg Therapeutics Stock FAQ

What is Tg Therapeutics's quote symbol?

(NASDAQ: TGTX) Tg Therapeutics trades on the NASDAQ under the ticker symbol TGTX. Tg Therapeutics stock quotes can also be displayed as NASDAQ: TGTX.

If you're new to stock investing, here's how to buy Tg Therapeutics stock.

What is the 52 week high and low for Tg Therapeutics (NASDAQ: TGTX)?

(NASDAQ: TGTX) Tg Therapeutics's 52-week high was $46.48, and its 52-week low was $16.21. It is currently -22.53% from its 52-week high and 122.15% from its 52-week low.

How much is Tg Therapeutics stock worth today?

(NASDAQ: TGTX) Tg Therapeutics currently has 158,755,036 outstanding shares. With Tg Therapeutics stock trading at $36.01 per share, the total value of Tg Therapeutics stock (market capitalization) is $5.72B.

Tg Therapeutics stock was originally listed at a price of $225.00 in May 3, 2010. If you had invested in Tg Therapeutics stock at $225.00, your return over the last 15 years would have been -84%, for an annualized return of -11.5% (not including any dividends or dividend reinvestments).

How much is Tg Therapeutics's stock price per share?

(NASDAQ: TGTX) Tg Therapeutics stock price per share is $36.01 today (as of Jun 13, 2025).

What is Tg Therapeutics's Market Cap?

(NASDAQ: TGTX) Tg Therapeutics's market cap is $5.72B, as of Jun 17, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Tg Therapeutics's market cap is calculated by multiplying TGTX's current stock price of $36.01 by TGTX's total outstanding shares of 158,755,036.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.